Denmark's Genmab has decided not to continue the development of a drug for cancer, acasunlimab, which had reached phase 3 testing, after a review of its medicines pipeline. The decision to end the ...
We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Andrea Barnes Andrea Barnes is a writer covering large cleaning appliances.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results